Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the stratall ANRS 12110/ESTHER trial in Cameroon

Clinical Infectious Diseases

Volumn 57, Issue 4, 2013, Pages 604-607

  Boullé, Charlotte ^a   Kouanfack, Charles ^b   Laborde Balen, Gabrièle ^a   Aghokeng, Avelin Fobang ^a,c   Boyer, Sylvie ^d,e,f   Carrieri, Maria Patrizia ^d,e,f   Kazé, Serge ^b   Mben, Jean Marc ^b   Dontsop, Marlise ^b   Spire, Bruno ^d,e,f   Peeters, Martine ^a   Mpoudi Ngolé, Eitel ^c   Delaporte, Eric ^a,g   Laurent, Christian ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b CENTRE HOSPITALIER   (France)

^c Institute of Medical Research and Medicinal Plant Studies Yaounde   (Cameroon)

^d INSERM   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Africa; Failure; HIV; Resistance; Switch

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CAMEROON; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

AFRICA; FAILURE; HIV; RESISTANCE; SWITCH;

ADULT; ANTI-HIV AGENTS; CAMEROON; CD4 LYMPHOCYTE COUNT; DECISION SUPPORT TECHNIQUES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HOSPITALS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RURAL POPULATION; VIRAL LOAD;

EID: 84880940593     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit323     Document Type: Article

References (15)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Accessed 19 May 2013.
2. Hamers RL, Sigaloff KCE, Kityo C, Mugyenyi P, de Wit TFR. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIVAIDS 2013; 8:19-26.
3. Médecins Sans Frontières (MSF). Untangling the web of antiretroviral price reductions. 15th ed. 2012; 1-120. Available at: http://aids2012. msf.org/wp-content/uploads/2012/07/MSF-Access-UTW-15th-Edition- 2012-webres.pdf. Accessed 19 May 2013.
4. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011; 53: 1283-90.
5. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
6. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
7. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49: 454-62.
8. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-7.
9. Laurent C, Kouanfack C, Laborde-Balen G, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised noninferiority trial. Lancet Infect Dis 2011; 11:825-33.
10. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Available at: http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed 18 April 2013.
11. Meresse M, Carrieri MP, Laurent C, et al. Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Antivir Ther 2013; 18:29-37.
12. French National Agency for Research on AIDS and Viral Hepatitis. HIV-1 genotypic drug resistance interpretation's algorithms, 2012. Available at: http://www.hivfrenchresistance.org/2012/tab1.html. Accessed 19 May 2013.
13. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviralresistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009; 48:1318-22.
14. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in Kwa Zulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-97.
15. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-17.